Suspected acute porphyria usually needs a spot urine sample for porphobilinogen, ALA and creatinine during symptoms—not just routine blood work. Specialized plasma, stool or red-cell tests answer different questions, particularly when sunlight-related skin symptoms are the main concern.
- First-line testing for suspected acute hepatic porphyria uses 3 measurements: urine porphobilinogen, ALA and creatinine.
- During symptoms is the most informative sampling window; collect before hemin when feasible, without delaying emergency treatment.
- Marked elevation of urine PBG, typically at least 5 times the laboratory upper limit in a compatible untreated episode, strongly supports an acute hepatic porphyria.
- Creatinine correction expresses urine results in units such as mg/g creatinine or µmol/mmol creatinine, reducing misleading effects from dilution.
- Sample protection means shielding urine from light and following the receiving laboratory's storage instructions, commonly refrigeration at 2–8°C.
- Negative results during an untreated attack are much more reassuring than negative results obtained weeks or months afterward.
- Skin-predominant disease may need plasma, urine and stool porphyrin fractionation; protoporphyria requires erythrocyte protoporphyrin testing.
- Emergency symptoms include new weakness, confusion, seizures or breathing difficulty; a sodium result below 125 mmol/L adds concern but is not required for urgency.
Can a routine porphyria blood test detect an acute attack?
A routine porphyria blood test does not reliably detect an acute attack because a CBC, metabolic panel and liver panel do not measure the 2 main acute-attack markers: porphobilinogen (PBG) and aminolevulinic acid (ALA). Suspected acute hepatic porphyria usually requires targeted urine testing during symptoms.
Routine blood tests identify complications and competing explanations, not the porphyria itself. A serum sodium of 122 mmol/L, for example, needs prompt assessment whether the cause is porphyria, medication effects or another illness; normal ALT and hemoglobin do not cancel the need for urine PBG when the symptoms fit.
A porphyria test order needs a named analyte and specimen, rather than the phrase 'check for porphyria.' The laboratory marker guide helps distinguish routine measurements from specialized assays, but the decisive question remains whether urine PBG and ALA were actually measured—not whether 20 other results were normal.
Kantesti is an AI blood test analyzer that can explain routine laboratory findings, but a missing urine PBG result cannot be reconstructed from a blood panel. I’m Thomas Klein, MD, and my clinical approach is to separate 2 questions: whether the patient has dangerous complications and whether the appropriate disease-specific test was ordered.
An educational example is a 29-year-old with recurrent severe abdominal pain, constipation and a fast pulse whose imaging has not found an explanation. Acute porphyria belongs on the differential, not at the top automatically; our organization should never turn a pattern of nonspecific blood results into a diagnosis.
Which symptoms justify an acute porphyria urine test?
An acute porphyria urine test is appropriate when otherwise unexplained severe abdominal pain occurs with neurological or autonomic features, such as weakness, constipation, tachycardia or hyponatremia. Recurrent episodes lasting more than 24 hours are particularly relevant, although an initial episode can also justify testing.
The AGA expert review recommends considering acute hepatic porphyria in women aged 15–50 years with recurrent severe abdominal pain unexplained after an initial workup, while recognizing that other patients can be affected (Wang et al., 2023). That age group helps prioritize testing; it is not an exclusion rule for men or older adults.
Normal pancreatic enzymes do not establish porphyria, and neither does an unrevealing abdominal scan. Our discussion of pain despite normal enzymes explains why the next step depends on the clinical pattern; a 2-day episode with new proximal weakness deserves different attention from brief pain after a meal.
A pulse of 115 beats/min, blood pressure of 165/95 mmHg and sodium of 128 mmol/L can occur together during an acute attack, but that combination has several other causes. I would use those findings to justify urgent clinical assessment and a targeted urine order, not to label the patient before the biochemical results return.
Dark urine is an unreliable screening sign: urine may look ordinary when freshly collected, and discoloration has many causes unrelated to porphyria. An episode diary recording 3 details—symptom onset, medicines or fasting, and collection time—often gives the specialist more useful information than a photograph of urine color.
What should the urine porphobilinogen test order include?
The initial urine porphobilinogen test should generally be quantitative and accompanied by urine ALA and creatinine on a random, or spot, specimen. These 3 measurements evaluate precursor accumulation while allowing the laboratory to account for urine concentration.
A practical request is: 'Random urine PBG, ALA and creatinine during current symptoms; report precursor-to-creatinine ratios.' Some laboratories include urine porphyrins in the initial panel, whereas the AGA review emphasizes the 3 precursor-focused measurements; ask which analytes the local package actually contains (Wang et al., 2023).
A routine urinalysis does not substitute for porphyria testing because its reagent strip does not measure PBG or ALA. The urine dipstick explanation can help decode the usual 8–10 screening fields, but a normal strip says nothing reliable about an acute hepatic porphyria.
Urobilinogen and porphobilinogen are different compounds, despite their similar names. Our urinalysis interpretation guide discusses urobilinogen; older Ehrlich-reagent methods require analytical safeguards because more than 1 urine compound can react, so an abnormal screening reaction needs appropriate confirmation.
A 24-hour collection is usually unnecessary for initial acute-attack testing and can delay an answer. If symptoms are happening now, a promptly collected spot specimen is generally preferable; ask the receiving laboratory about the minimum volume, because its validated requirements—not a universal internet figure—should guide collection.
When is urine testing most likely to detect an attack?
Urine PBG and ALA testing is most informative during a compatible symptomatic episode, preferably before porphyria-specific treatment. There is no need to wait for a fasting appointment or a 24-hour collection, and specimen collection must not delay emergency care.
Hemin suppresses hepatic precursor production, and givosiran can lower ALA and PBG substantially; treatment therefore changes the meaning of a negative result. Recording the time of the last dose and the urine collection gives the specialist 2 essential timestamps that a generic 'normal porphyria screen' report may omit.
PBG may remain elevated for months or years after an acute intermittent porphyria attack, while it can fall more quickly after attacks of hereditary coproporphyria or variegate porphyria. That difference explains why the timing of laboratory changes matters: one sampling schedule does not suit all 3 conditions.
A pretreatment sample is helpful even when an urgent result is not available locally. In a hypothetical 36-year-old with progressive weakness and severe abdominal pain, I would want the specimen collected promptly and stored correctly while the emergency team evaluates other causes; waiting 48 hours for a send-away result is not an emergency-care plan.
Deliberate fasting is not a diagnostic preparation step for this test and can trigger attacks in susceptible people. If a patient is already following a fasting instruction for a separate blood panel, the clinician should reconcile the 2 orders rather than assuming that the urine test also requires fasting.
How are urine PBG and ALA results interpreted?
Urine PBG and ALA results should be interpreted against the laboratory’s reference limits and, usually, expressed relative to urine creatinine. In a compatible untreated episode, PBG at least 5 times the upper limit of normal strongly supports an acute hepatic porphyria, but does not determine its subtype.
The same amount of excreted PBG can produce different concentration results after different fluid intake. Reporting mg/g creatinine or µmol/mmol creatinine helps compensate for that effect; our urine creatinine explanation describes why a ratio often tells more than an isolated mg/L value.
A reference limit of 2 mg/g creatinine, if used by a particular laboratory, would make 10 mg/g creatinine five times its upper limit. Those figures are an arithmetic example, not a universal PBG range; using another laboratory’s cutoff against a result in µmol/mmol can create a substantial interpretation error.
Very dilute urine can still cause problems even after creatinine correction because measurement near an assay’s detection limit is less reliable. Anderson’s diagnostic review discusses how a specimen with creatinine below about 0.2 g/L may be unsuitable for straightforward interpretation; the laboratory should advise whether repeat sampling is needed (Anderson, 2019).
Kantesti is an AI blood test interpretation platform, not a validated porphyria diagnostic assay, and no ratio should be interpreted without its units and sampling context. PBG that is 10 times the upper limit in a known high excretor does not, by itself, prove that today’s unrelated headache is a new attack.
How should a porphyria urine sample be handled?
A porphyria urine sample should be protected from light, promptly transported and stored according to the receiving laboratory’s instructions. Refrigeration at 2–8°C is commonly used for short-term storage, but acceptable delays, freezing and preservatives depend on the assay.
An opaque container or foil wrapped around the container protects the specimen better than placing a clear cup on a sunny windowsill. Light exposure particularly affects porphyrins, and storage conditions can also affect precursor testing; use 1 collection pathway approved by the laboratory rather than improvising several different storage steps.
The receiving laboratory should decide whether a delay beyond 24 hours requires freezing or another arrangement. Some laboratories validate longer refrigerated stability, while others specify stricter transport conditions; a laboratory’s written stability limit is more useful than a blanket claim that every porphyria specimen remains reliable for several days.
Preservative requirements differ between assays, so patients should not add acid, disinfectant or another substance themselves. Specialized handling is not unique to porphyria—the ACTH collection guide shows the same principle—but an instruction for 1 hormone assay must never be transferred automatically to a urine PBG assay.
A useful collection record contains 4 facts: symptom status, collection time, relevant treatment and any storage problem. If an unprotected sample spent 6 hours in warm direct light, tell the clinician and laboratory; whether it needs repeating depends on the analytes and method, not simply on how normal the final report looks.
What do high PBG, high ALA or high porphyrins mean?
Markedly elevated PBG supports acute intermittent porphyria, hereditary coproporphyria or variegate porphyria in the appropriate setting. ALA elevation without substantial PBG elevation points toward a different differential, including lead exposure and the extremely rare ALA dehydratase deficiency porphyria.
An isolated high ALA result needs confirmation and context, not an automatic acute intermittent porphyria label. At least 3 possibilities merit consideration: lead-related inhibition of heme synthesis, ALA dehydratase deficiency porphyria and, in an appropriate pediatric setting, hereditary tyrosinemia type 1; additional tests depend on exposure and presentation.
Lead exposure can mimic parts of the abdominal and neurological presentation of porphyria while usually leaving PBG comparatively normal. The heavy-metal testing guide explains why the right specimen and exposure history matter; a blood lead result in µg/dL answers a different question from urine ALA in mg/g creatinine.
A mild rise in total urine porphyrins is not equivalent to a high PBG result. Liver disease and other acquired conditions can produce secondary porphyrinuria, so a result 1.5 times the porphyrin upper limit should not be used to diagnose an acute attack without reviewing the actual fractions and precursor results.
A quantitative result supplies more information than a simple positive screening reaction. Our explanation of qualitative versus quantitative results is relevant here: 'positive' does not reveal whether an analyte is 1.2 or 20 times its upper limit, and that distinction can change the next clinical step.
Does a negative urine test rule out acute porphyria?
Normal quantitative urine PBG and ALA during an untreated symptomatic episode, from a reliable specimen, make a typical acute hepatic porphyria attack very unlikely. A negative test obtained weeks or months between episodes is less informative, particularly for hereditary coproporphyria and variegate porphyria.
A negative PBG result alone does not address every acute porphyria because ALA dehydratase deficiency porphyria can raise ALA without raising PBG substantially. That rare exception is 1 reason to request both precursors rather than treating a lone 'PBG negative' entry as an exhaustive assessment.
The strength of a negative result depends on 3 checks: whether symptoms were active, whether the sample was suitable and whether treatment had already suppressed precursor production. The meaning of normal results is always test-specific; normal values are reassuring only for the condition and window the test can evaluate.
Persistent precursor elevation is more common in acute intermittent porphyria than in the other common acute hepatic subtypes, but some people with AIP can have normal results while well. A sample collected 3 months after an episode cannot retrospectively prove what caused it; a specialist may arrange testing during the next episode if the history remains persuasive.
Kantesti AI should not interpret a normal sodium result or a negative off-episode report as proof that recurrent symptoms are harmless. After 2 appropriately collected, untreated symptomatic episodes with normal PBG and ALA, a clinician should actively reconsider alternative explanations rather than endlessly repeating the same porphyria screen.
How is acute intermittent porphyria diagnosis confirmed?
Acute intermittent porphyria diagnosis begins with appropriate biochemical testing; an HMBS pathogenic variant can then confirm the inherited subtype. The 3 more common acute hepatic porphyrias involve HMBS in AIP, CPOX in hereditary coproporphyria and PPOX in variegate porphyria.
A pathogenic variant establishes susceptibility, but it does not establish that a current symptom is an acute attack. The AGA review estimates symptomatic penetrance at approximately 1% among AIP variant carriers in population-based settings, with higher estimates in affected families; the source population therefore changes what a positive genetic result predicts (Wang et al., 2023).
Biochemical confirmation before broad genetic testing reduces confusion from incidental findings and variants of uncertain significance. Our discussion of genetic variant interpretation concerns a different gene, but illustrates 1 transferable principle: a genetic finding must be matched to the mechanism, evidence and clinical question.
Targeted family testing is an exception to the usual biochemical-first pathway when a relative already has a confirmed pathogenic variant. For autosomal dominant AIP, HCP or VP, each child of a carrier has a 50% chance of inheriting the variant; that is not a 50% chance of developing clinical attacks.
AIP typically causes neurovisceral illness without photosensitive skin disease, whereas HCP and VP can produce both acute and cutaneous manifestations. A patient with 2 kinds of symptoms therefore needs a broader subtype assessment; blistering does not automatically mean the acute abdominal episodes are unrelated.
How do acute and cutaneous porphyria tests differ?
Acute porphyrias are investigated primarily through precursor accumulation during neurovisceral symptoms, while cutaneous porphyrias need testing directed at light-sensitive porphyrins. Porphyria cutanea tarda typically causes fragile, blistering sun-exposed skin; erythropoietic protoporphyria more often causes rapid burning discomfort after light exposure.
Porphyria cutanea tarda does not cause the acute neurovisceral attacks characteristic of AIP, HCP and VP. Its laboratory pattern usually includes increased urinary uroporphyrin and heptacarboxyl porphyrins, with additional plasma or stool testing when needed; a normal PBG result does not rule out PCT (Balwani and Desnick, 2012).
Protoporphyria can cause symptoms within minutes of sunlight exposure even when visible skin changes are limited. A person describing 15 minutes outdoors followed by burning discomfort deserves a different assessment from someone with an itchy rash developing overnight; our itchy-skin testing discussion explains why symptom descriptions matter.
A patient with suspected PCT needs evaluation of contributing factors, including iron status, liver disease, hepatitis C, HIV and relevant medication or estrogen exposure. These are supporting investigations, not replacements for porphyrin testing; a ferritin of 450 ng/mL alone cannot establish PCT or justify treatment.
The acute-versus-cutaneous distinction is not a perfect 2-box classification because HCP and VP overlap. I would ask explicitly about sun-exposed skin fragility in someone being investigated for acute attacks, and about abdominal or neurological episodes in someone referred for possible cutaneous porphyria.
When do plasma or red-cell porphyria tests help?
Plasma porphyrin testing helps assess suspected cutaneous porphyria and distinguish some subtypes, while erythrocyte protoporphyrin testing is central to diagnosing protoporphyria. A plasma fluorescence peak around 624–627 nm is characteristic of variegate porphyria when interpreted by a specialist laboratory.
A specialized plasma test is genuinely a porphyria blood test, but it is not the same as a routine liver panel. The serum and plasma explanation clarifies specimen differences; fluorescence scanning analyzes emitted light across wavelengths rather than the 10–15 routine chemistry measurements many patients expect.
Erythropoietic protoporphyria usually requires measurement of total erythrocyte protoporphyrin and separation into metal-free and zinc-bound fractions. Protoporphyrin is poorly water-soluble and is not appreciably excreted in urine, so a normal urine porphyrin result cannot exclude EPP; the correct cellular assay matters more than collecting more urine.
A zinc protoporphyrin screening assay alone can miss or mischaracterize protoporphyria because it does not adequately answer the metal-free protoporphyrin question. FECH-related EPP and ALAS2-related X-linked protoporphyria have different fraction patterns, so the laboratory should measure both forms rather than supplying only 1 nonspecific total.
Kantesti’s explanation of a routine panel should not be mistaken for validation of a plasma fluorescence scan or erythrocyte porphyrin method. In severe kidney dysfunction or anuria, a specialist may also use validated plasma ALA and PBG assays because urine ratios become problematic; that is a targeted alternative, not a reason to order a generic blood screen.
When does stool testing help identify the porphyria type?
Stool porphyrin fractionation helps distinguish porphyria subtypes after an abnormal screen or when cutaneous disease is suspected. Hereditary coproporphyria commonly shows excess fecal coproporphyrin III, while variegate porphyria often raises both fecal protoporphyrin and coproporphyrin.
Fecal subtype testing measures specific porphyrins and their relative proportions, not a general digestive-health signal. The 2 major copro isomers, I and III, can provide more discriminating information than total coproporphyrin alone; the laboratory must interpret the pattern using its validated method and reference data (Anderson, 2019).
A stool porphyrin test is not interchangeable with calprotectin, a culture or an occult-blood test. Our stool-test comparison discusses 2 inflammatory markers, neither of which identifies porphyria; the request needs to specify porphyrin fractionation rather than simply 'send a stool sample.'
Fecal isocoproporphyrin can support PCT classification when interpreted alongside urine and plasma findings. However, intestinal processes and analytical differences can complicate stool patterns, so a borderline isolated fraction should not outweigh 3 coherent sources of evidence: the phenotype, precursor results and the broader porphyrin profile.
Stool testing should not postpone urine PBG and ALA collection during a suspected acute attack. The sequence is practical: obtain the first-line symptomatic specimen now, then add plasma, stool or genetics to answer the subtype question; waiting 2 days for a stool specimen can lose a useful urine-testing window.
What happens after a positive result or severe symptoms?
A strongly positive symptomatic urine result requires prompt clinical assessment and porphyria-specialist input; new weakness, confusion, seizures or breathing difficulty require emergency care regardless of test availability. Sodium below 125 mmol/L increases concern, but serious attacks can occur without that finding.
Hyponatremia during an attack can reflect inappropriate antidiuretic hormone activity, vomiting, fluid management or several mechanisms together. Our low-sodium warning signs explain why confusion at 124 mmol/L needs urgent evaluation; sodium correction must be supervised because overly rapid correction can itself cause neurological injury.
Severe attacks are generally treated with intravenous hemin under specialist care, commonly 3–4 mg/kg daily for 4 days, depending on the product and protocol (Wang et al., 2023). That is a treatment regimen, not a self-management instruction; collecting the diagnostic specimen first is desirable only when it does not delay necessary treatment.
Regular nutrition and avoiding prolonged fasting reduce a recognized trigger, but eating carbohydrates is not an adequate response to progressive weakness or a severe attack. A 3-meal eating pattern may be practical for some patients; the right plan depends on diabetes, kidney disease and other conditions, rather than a universal high-sugar prescription.
A confirmed diagnosis should lead to medication-safety review, trigger counseling and an individualized follow-up plan. For acute hepatic porphyria, the AGA review recommends liver-cancer surveillance beginning at age 50, usually with liver ultrasound every 6 months; that recommendation does not apply automatically to everyone who once had borderline urine porphyrins.
What should you ask your doctor about porphyria testing?
Ask whether your symptoms call for acute precursor testing, cutaneous porphyrin testing or both, and whether the sample can be collected while symptoms are active. As of October 3, 2026, the practical first-line approach described here remains consistent with the 2023 AGA expert review.
A useful appointment checklist has 4 questions: 'Were PBG and ALA measured?', 'Was urine creatinine included?', 'Was I symptomatic and untreated?', and 'Does this result require subtype testing?' My advice as Thomas Klein, MD, is to bring the complete report, including units and reference limits, rather than a cropped positive-or-negative screenshot.
Kantesti is an AI lab test interpretation service for explaining supplied laboratory reports, not a substitute for specialist porphyria diagnosis. Our technology explanation describes the interpretation workflow; for this condition, 2 safeguards remain indispensable: verify that the required test exists and verify that its specimen timing was appropriate.
Kantesti’s supporting explanations should be evaluated against their stated limits, not assumed to diagnose a rare disorder. Our clinical standards information provides methodology context. The medical advisory board identifies our medical advisers, while urgent symptoms still require direct care—not waiting approximately 60 seconds for an automated explanation.
Related Kantesti research publications
The 2 Figshare publications below are related educational resources, not clinical evidence validating porphyria diagnosis or proving the accuracy of porphyria interpretation. The hematology marker publication addresses routine hematology. The digestive symptom publication addresses gastrointestinal questions; their DOI records are listed separately from the directly relevant medical references.
Frequently Asked Questions
Can a blood test diagnose porphyria?
Specialized blood-based tests can help diagnose certain porphyrias, but a routine CBC, metabolic panel or liver panel cannot exclude an acute attack. Suspected acute hepatic porphyria usually requires 3 spot-urine measurements: PBG, ALA and creatinine. Plasma porphyrins and erythrocyte protoporphyrin answer different questions, particularly when sunlight-related symptoms predominate. Severe kidney dysfunction may require specialist-selected plasma precursor testing.
What is the best urine test for acute intermittent porphyria?
The preferred initial test for suspected acute intermittent porphyria is quantitative urine PBG with urine ALA and creatinine, collected during symptoms. A spot specimen is usually sufficient; a 24-hour collection generally adds delay without improving initial diagnosis. PBG at least 5 times the laboratory upper limit strongly supports an acute hepatic porphyria in a compatible untreated episode. Further biochemical assessment and HMBS genetic testing help confirm AIP rather than another acute subtype.
Can porphyria urine testing be negative between attacks?
Porphyria urine testing can be negative between attacks, especially in hereditary coproporphyria and variegate porphyria. Acute intermittent porphyria can also have normal precursor results while a person is well, although elevations may persist for months or years. A negative sample collected 3 months after symptoms is therefore less informative than one collected during an untreated episode. If suspicion remains justified, a specialist may arrange repeat testing during symptoms.
Does a normal urine PBG rule out all porphyrias?
A normal urine PBG result does not rule out every porphyria. PCT and protoporphyria require different testing, and the extremely rare ALA dehydratase deficiency porphyria can produce high ALA without substantial PBG elevation. Normal PBG and ALA together during an untreated symptomatic episode, with appropriate handling, make a typical acute hepatic attack very unlikely. The 2 precursor results must be interpreted alongside symptom timing, treatment and specimen suitability.
How do I collect and store a porphyria urine sample?
Use the receiving laboratory’s collection instructions, protect the urine container from light and arrange prompt transport. Refrigeration at 2–8°C is commonly appropriate for short-term storage, but freezing, preservatives and acceptable delays depend on the assay. Do not add acid or another substance unless the laboratory has supplied and instructed its use. Record symptom status and relevant treatment so the result can be matched to the collection window.
Do high urine porphyrins mean I have an acute porphyria attack?
High total urine porphyrins alone do not establish an acute porphyria attack. Mild elevations, such as 1.5 times the laboratory upper limit, can occur with liver disease and other acquired conditions. Quantitative PBG and ALA are more useful for assessing suspected acute attacks, while porphyrin fractionation helps classify cutaneous and overlapping disorders. A specialist should interpret the pattern rather than treating every flagged porphyrin value as diagnostic.
When should suspected porphyria symptoms be treated as an emergency?
Suspected porphyria symptoms require emergency assessment when severe abdominal pain is accompanied by new weakness, confusion, seizures, breathing difficulty or inability to maintain hydration. A sodium result below 125 mmol/L adds concern, but a normal sodium result does not make progressive neurological symptoms safe to observe at home. Clinicians should obtain a pretreatment urine specimen when feasible without delaying necessary care. A send-away porphyria result is not a reason to postpone assessment for other urgent abdominal or neurological conditions.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). B Negative Blood Type, LDH Blood Test & Reticulocyte Count Guide. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Diarrhea After Fasting, Black Specks in Stool & GI Guide 2026. Kantesti AI Medical Research.
📖 External Medical References
Wang B et al. (2023). AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology.
Anderson KE (2019). Acute hepatic porphyrias: Current diagnosis & management. Molecular Genetics and Metabolism.
Balwani M and Desnick RJ (2012). The porphyrias: advances in diagnosis and treatment. Blood.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.